Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ileal sodium-dependent bile acid transporter (IBAT/ASBT), encoded by the SLC10A2 gene, is a membrane-bound symporter responsible for the active reabsorption of bile acids from the lumen of the small intestine (ileum) using a sodium gradient. It plays a critical role in maintaining enterohepatic circulation by reclaiming both conjugated and unconjugated bile acids back into enterocytes for return to the liver, which is essential for efficient digestion and absorption of dietary lipids. Reduced expression or function leads to increased fecal loss of bile acids, potentially resulting in diarrhea or fat malabsorption. IBAT/ASBT inhibitors are being developed as treatments for chronic constipation, irritable bowel syndrome, and non-alcoholic steatohepatitis (NASH).
Inhibition of IBAT/ASBT, Glucocorticoid-induced transcriptional upregulation, PKCζ-mediated posttranslational modulation
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ileal Sodium-Dependent Bile Acid Transporter (IBAT).